Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colciaghi, F.
Right arrow Articles by Di Luca, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colciaghi, F.
Right arrow Articles by Di Luca, M.
Related Collections
Right arrow Alzheimer's disease
NEUROLOGY 2004;62:498-501
© 2004 American Academy of Neurology
Brief Communications

Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease

F. Colciaghi, PhD*, E. Marcello, PhD*, B. Borroni, MD, M. Zimmermann, PhD, C. Caltagirone, MD, F. Cattabeni, PhD, A. Padovani, MD PhD and M. Di Luca, PhD

From the Centre of Excellence on Neurodegenerative Disorders and Department of Pharmacological Sciences (Drs. Colciaghi, Marcello, Zimmermann, Cattabeni, and Di Luca), School of Pharmacy, University of Milan; Department of Medical Sciences-Neurology Unit (Drs. Borroni and Padovani), School of Medicine, University of Brescia; and University Roma Tor Vergata and IRCCS Santa Lucia (Dr. Caltagirone), Rome, Italy.

Address correspondence and reprint requests to Dr. Monica Di Luca, the Centre of Excellence on Neurodegenerative Disorders and Department of Pharmacological Sciences, University of Milan, School of Pharmacy, via Balzaretti, 9-20133 Milan, Italy; e-mail: Monica.Diluca{at}unimi.it

Amyloid precursor protein (APP), ADAM 10, and ß-site-APP cleaving enzyme (BACE) alterations were evaluated in platelets of 31 patients with Alzheimer disease (AD) and 15 age-matched controls. A significant modification of these proteins and enzymes involved in the amyloid cascade was detected from the earliest clinically detectable disease stage. This observation suggests that AD is associated with an early metabolic derangement toward amyloidogenic pathways and supports the potential value of APP and secretase measurements for early diagnosis of AD.

Received May 16, 2003. Accepted in final form September 24, 2003.

*These authors contributed equally to this work.




This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. K. Andrews, D. Karunakaran, E. E. Gardiner, and M. C. Berndt
Platelet Receptor Proteolysis: A Mechanism for Downregulating Platelet Reactivity
Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1511 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. F. Obregon, K. Rezai-Zadeh, Y. Bai, N. Sun, H. Hou, J. Ehrhart, J. Zeng, T. Mori, G. W. Arendash, D. Shytle, et al.
ADAM10 Activation Is Required for Green Tea (-)-Epigallocatechin-3-gallate-induced {alpha}-Secretase Cleavage of Amyloid Precursor Protein
J. Biol. Chem., June 16, 2006; 281(24): 16419 - 16427.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. E. Gardiner, J. F. Arthur, M. L. Kahn, M. C. Berndt, and R. K. Andrews
Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase
Blood, December 1, 2004; 104(12): 3611 - 3617.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.